港股異動 | 協鑫科技一度漲約6% 協鑫顆粒硅產出量連創新高
格隆匯10月13日丨協鑫科技(3800.HK)盤初一度拉昇漲約6%,現報2.21港元,暫成交1.62億港元,總市值近600億港元。據悉,隨着樂山協鑫10萬噸顆粒硅基地產能穩步提升,該公司顆粒硅日產量已達251噸,基本上日生產日出貨,產出量連創新高。至2022年底,協鑫科技顆粒硅總產能將達26萬噸。在產量創新高同時,顆粒硅產品質量也有所升級。目前客户反饋積極,產品供不應求。值得一提的是,董事會已批准發行A股的初步提議。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.